Retraction

IF 3.3 4区医学 Q2 HEMATOLOGY Hematological Oncology Pub Date : 2024-04-29 DOI:10.1002/hon.3276

{"title":"Retraction","authors":"","doi":"10.1002/hon.3276","DOIUrl":null,"url":null,"abstract":"Retraction: “Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma” by Picardi, M., Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A. and Pane, F., Hematol Oncol., 2024; 42: e3247. https://doi.org/10.1002/hon.3247.The above article from Hematological Oncology, published online on 24 January 2024 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's editor-in-chief, Francesco Bertoni, the authors, and John Wiley & Sons Ltd. This action has been agreed due to an error at the publishers which caused this duplicate of another article to be published. The correct version of the article, first published online on 21 December 2023, is to be found at: “Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma” by Picardi, M., Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A. and Pane, F., Hematol Oncol., 2024; 42: e3242. https://doi.org/10.1002/hon.3242.","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3276","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3276","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Retraction: “Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma” by Picardi, M., Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A. and Pane, F., Hematol Oncol., 2024; 42: e3247. https://doi.org/10.1002/hon.3247.

The above article from Hematological Oncology, published online on 24 January 2024 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's editor-in-chief, Francesco Bertoni, the authors, and John Wiley & Sons Ltd. This action has been agreed due to an error at the publishers which caused this duplicate of another article to be published. The correct version of the article, first published online on 21 December 2023, is to be found at: “Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma” by Picardi, M., Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A. and Pane, F., Hematol Oncol., 2024; 42: e3242. https://doi.org/10.1002/hon.3242.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

撤回

撤稿："原发性纵隔大B细胞淋巴瘤和纵隔灰区淋巴瘤的脂质体包封多柔比星超荷一线治疗提高了反应率》，作者：Picardi, M..、Giordano, C.、Pugliese, N.、Mascolo, M.、Varricchio, S.、Troncone, G.、Vigliar, E.、Bellavicine, C.、Lamagna, M.、Lisi, D.、Vincenzi, A.和 Pane, F、Hematol Oncol., 2024; 42: e3247. https://doi.org/10.1002/hon.3247.The 上述文章来自《血液肿瘤学》，于2024年1月24日在线发表于Wiley Online Library (wileyonlinelibrary.com)，经杂志主编Francesco Bertoni、作者和John Wiley & Sons Ltd.同意，已被撤回。之所以同意采取这一行动，是因为出版商出了差错，导致这篇与另一篇文章重复的文章被发表。该文章的正确版本于 2023 年 12 月 21 日首次在线发表，可在以下网址找到："含多柔比星脂质体的一线治疗提高了原发性纵隔大B细胞淋巴瘤和纵隔灰区淋巴瘤的应答率》，作者：Picardi, M..、Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A. and Pane, F., Hematol Oncol., 2024; 42: e3242. https://doi.org/10.1002/hon.3242.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.